RHHBY Stock UPDATES Roche Hldg Ltd Spons (RHHBY) 36.4480 08/20/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Roche Hldg Ltd Spons (RHHBY) 36.4480 $RHHBY

Biotech Stock Roundup: Achillion Scores in Mid-Stage Study, Gilead's Sovaldi Remains in Focus - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 20, 10:08AM CDT
Last week, hepatitis C virus treatments remained in focus with Achillion and Gilead providing updates on ACH-3102 and Sovaldi, respectively.

Will Roche (RHHBY) Buy the Remaining Stake in Chugai? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 19, 4:55PM CDT
As per a news report from Bloomberg, Switzerland-based oncology major, Roche (RHHBY) is set to buy the remaining 39.5% stake in its Japanese subsidiary, Chugai Pharmaceutical Co Ltd for approximately $10 billion.

PDL BioPharma Misses on Q2 Earnings due to Higher Expenses - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 19, 8:10AM CDT
PDL BioPharma (PDLI) posted second-quarter 2014 earnings of 52 cents per share, below the Zacks Consensus Estimate of 55 cents.

Roche's Avastin Approved by FDA for Advanced Cervical Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 1:30PM CDT
Roche (RHHBY) received positive news when the FDA approved Avastin in combination with paclitaxel and cisplatin or paclitaxel and topotecan for the treatment of women with persistent, recurrent or metastatic carcinoma of the cervix.

Gilead Scores Legal Victory Over Roche for Sovaldi, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 12:34PM CDT
Gilead (GILD) received a favorable verdict on Sovaldi.

Why Chugai Pharmaceutica (CHGCY) Stock Is Down Today
at The Street - Mon Aug 18, 10:42AM CDT
Shares of Chugai Pharmaceutica (CHGCY) are down after the company denied reports that its parent Roche Holding (RHHBY) was said to be in talks to buy out the Japanese drugmaker.

Chugai Denies Talk of Roche Bid, but Market Unconvinced
at The Street - Mon Aug 18, 8:36AM CDT
Japanese drugmaker Chugai Pharmaceutical sees its stock rise, despite strenuous denials that its majority shareholder Roche wants to take it private.

Gilead Wins Sovaldi Dispute With Roche, U.K. Nod
at Investor's Business Daily - Fri Aug 15, 4:44PM CDT
Big-cap biotech Gilead Sciences (GILD) rose 3.2% to 99.49 on the stock market today, hitting a new all-time high Friday after it won a dispute with Roche over rights to its blockbuster hepatitis C drug, which separately was endorsed by the U.K.'s...

Stocks End Mixed, Off Session Lows; FleetCor Pads Gains
at Investor's Business Daily - Fri Aug 15, 3:32PM CDT
Stocks pared losses Friday after a harsh reminder that Ukraine, even when it goes to the back burner for a while, remains an area of concern for the market. Two days after the Nasdaq flashed a sign of strength, stocks reversed early gains, but...

FDA Approves Genentech's Avastin Plus Chemotherapy for Treatment of Advanced Cervical Cancer
Business Wire - Thu Aug 14, 2:52PM CDT
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Avastin(R) (bevacizumab) in combination with paclitaxel and cisplatin or paclitaxel and topotecan for the treatment of women with persistent, recurrent or metastatic carcinoma of the cervix.

Halozyme Gains on Narrower-than-Expected Loss, Revenues Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 9:53AM CDT
The company's second quarter 2014 loss came in at 13 cents per share, narrower than the year-ago loss of 20 cents per share and the Zacks Consensus Estimate of a loss of 18 cents per share.

Why InterMune (ITMN) Stock Is Down Today
at The Street - Thu Aug 14, 7:14AM CDT
The biotech was downgraded to 'neutral' on valuation at Goldman Sachs Group (GS)..

Intermune up on buyout buzz
at Investor's Business Daily - Wed Aug 13, 5:58PM CDT
Switzerland-based Roche (RHHBY), the world's No. 1 drugmaker by market cap, and France's Sanofi (SNY) are reportedly among the suitors for InterMune (ITMN). U.K.-based GlaxoSmithKline (GSK) is also said to be bidding. InterMune is mulling options and...

Genentech Submits Supplemental Biologics License Application to FDA for Lucentis Indication in Diabetic Retinopathy
Business Wire - Fri Aug 08, 10:30AM CDT
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the company has submitted a supplemental Biologics License Application (sBLA) for Lucentis(R) (ranibizumab injection) to the U.S. Food and Drug Administration (FDA) for the treatment of diabetic retinopathy. The submission is based on results of the RISE and RIDE Phase III clinical trials demonstrating the safety and efficacy of Lucentis for this serious eye disease. There are currently no ocular medications approved for the treatment of diabetic retinopathy.

Small companies lead the I-O class of Cancer Therapies
ACCESSWIRE - Fri Aug 08, 7:02AM CDT
Los Angeles, CA / August 8, 2014 / Tumor cells, tending to persist after treatment, lead to remission and have been a bane to cancer researchers and doctors for decades. Only recently, immuno-oncology, labeled 'I-O' first by Bristol-Myers Squibb Company (NYSE:BMY) has emerged to become a new class of cancer medicines that may someday take a meaningful place alongside chemotherapy, surgery, and radiation.

Isis Pharmaceuticals Posts Narrower-Than-Expected Q2 Loss - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Aug 07, 8:10AM CDT
Isis Pharmaceuticals (ISIS) remains on track to deliver revenues of more than $160 million this year.

Roche to Acquire Santaris Pharma to Expand RNA Portfolio - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 05, 4:45PM CDT
In a bid to expand the discovery and development of RNA-targeting medicines, Roche (RHHBY) announced that it has entered into an agreement to acquire Denmark-based privately-held biopharmaceutical company Santaris Pharma.

ImmunoGen Q4 Loss Narrower than Expected, Provides Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 04, 1:50PM CDT
ImmunoGen (IMGN) reported fourth quarter loss of 31 cents per share, narrower than the Zacks Consensus Estimate of a loss of 36 cents.

Will Roche (RHHBY) Stock Be Helped By Santaris Pharma Acquisition?
at The Street - Mon Aug 04, 11:26AM CDT
Roche Holding (RHHBY) said it will buy Santaris Pharma, a privately-held Danish biotech company, for up to $450 million in cash.

Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo
PR Newswire - Tue Jul 29, 9:44AM CDT
Roche (SIX: RO, ROG; OTCQX: RHHBY) launched its presence at the American Association for Clinical Chemistry (AACC) 2014 Clinical Lab Expo today by unveiling two booths (#1209 and #2009) focused on the unique ways Roche is partnering with customers to redefine the value of the laboratory.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

AV Access iDock B12 Chases the Growing Two-PC Desk Boom

Updated Category News Views 136

Cable spaghetti has become an oddly durable tax on anyone running a work laptop beside a gaming tower, and AV Access is taking a proper swing at it with the iDock B12. This is not some mystical new category; it is a KVM switch and docking station mashed together for a desk that has to serve two masters. Still, the company has aimed at the parts that usually get sacrificed...

Continue Reading
Shenzhen Three-Way Summit Puts Stability to the Test

Updated Category News Views 191

Three nuclear powers sharing a room in Shenzhen is the sort of headline that makes every risk desk sit upright, even when the paperwork remains thin. CGTN reports that Chinese President Xi Jinping, Russian President Vladimir Putin and U.S. President Donald Trump met on November 19, 2026, in an unprecedented trilateral summit and issued a Declaration toward Peace. That is...

Continue Reading
T. Rowe Price Expands Teams Across 12 Fund Strategies

Updated Category News Views 96

A Quiet Personnel Shift With Real Stakes Twelve strategy changes may sound like administrative wallpaper, but asset managers live and die by who makes the calls. T. Rowe Price is broadening portfolio-management teams across equity and fixed-income offerings while insisting that each strategy's philosophy, process, and risk limits remain intact. Fine. That is the stated...

Continue Reading
Makers Nutrition Backs Families Through Friends of Karen

Updated Category News Views 79

A thousand dollars in gift cards can look modest beside the noise of holiday marketing, but it lands differently when a family is carrying the weight of a child’s life-threatening illness. Makers Nutrition, a Hauppauge, New York-based private-label and custom supplement manufacturer, has donated $1,000 in gift cards to Friends of Karen for the nonprofit’s annual...

Continue Reading
Lieda Shadwick’s Career Education Work Earns 2026 Honor

Updated Category News Views 76

Twenty-six years in classrooms is not the sort of accomplishment that needs fireworks to carry weight. Lieda A. Shadwick’s recognition as The Inner Circle’s 2026 Educator of the Year points to a career built around a stubbornly important idea: students need more than academic vocabulary if they are going to navigate work, leadership, and business with any confidence....

Continue Reading
Ductless Mini-Splits Put HVAC Efficiency Into Focus

Updated Category News Views 46

Ductless mini-splits have slipped from contractor jargon into a serious conversation about how homes and smaller buildings are heated and cooled. That is the worthwhile backdrop for a HelloNation article featuring HVAC expert Natasha Adams. The source notes are lean—really lean—and do not spell out her specific guidance, product comparisons, efficiency figures,...

Continue Reading
Fermi Board Fight Tests Texas Governance Standards Again

Updated Category News Views 60

A boardroom rulebook is supposed to restrain power, not become a trapdoor under shareholders’ feet. That is the ugly governance question hanging over Fermi after the Texas Business Court dismissed Toby Neugebauer’s challenge to the company’s 70% supermajority bylaw. Neugebauer, Fermi’s co-founder and largest shareholder, says he will appeal. Frankly, he has every...

Continue Reading
Decibel's Export Engine Masks a Domestic Sales Slip

Updated Category News Views 134

Decibel’s overseas business is doing the heavy lifting, and it is not doing it quietly. Third-quarter net revenue reached $35.1 million, up 7% from a year earlier, while international sales jumped 44% to a record $12.1 million. That split matters more than the headline. Canadian adult-use sales fell 6% to $23.0 million, which means the company is proving it can find...

Continue Reading
Point72 Breach Puts Cyber Controls Under the Microscope

Updated Category News Views 101

Two compromised user accounts can turn a supposedly contained cyber problem into a boardroom headache in a hurry. Point72 Asset Management, the global alternative-investment firm founded by Steven A. Cohen in 2014, has reported a social-engineering incident involving accounts that were used to copy files from limited portions of its IT systems. This is not a trading-loss...

Continue Reading
Trip.Best Expands Global Travel Discovery Footprint

Updated Category News Views 105

Sydney just became the map pin for a fairly serious travel-content land grab. Trip.Best, Trip.com Group's ranking brand, has rolled out its 2027 Annual Rankings with coverage of all seven continents for the first time. This is not an earnings release, and nobody should pretend a hotel list magically turns into revenue by lunchtime. Still, the jump from 85 to 98 annual...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding the Investigation into iTeos Therapeutics Acquisition

Updated Category News Views 182

Investigation Overview of iTeos Therapeutics, Inc. Rowley Law PLLC is currently delving into possible violations of securities laws involving iTeos Therapeutics, Inc. (NASDAQ: ITOS) and its board of directors regarding the proposed acquisition by Concentra Biosciences, LLC. This acquisition aims to provide stockholders with $10.047 for each share they hold, accompanied by...

Continue Reading
Ares Management Joins S&P 500; Changes in SmallCap 600

Updated Category News Views 483

Ares Management Join the S&P 500 In an exciting development for investors, Ares Management (NYSE: ARES) will be joining the S&P 500 index shortly. This news comes as Kellanova (NYSE: K) has announced its acquisition by Mars Inc., which has precipitated the need for these changes in the index. Ares Management is making a mark in the financial sector and its inclusion...

Continue Reading
Berkshire Hathaway's Q3 Earnings Report: Key Insights Revealed

Updated Category News Views 113

Berkshire Hathaway's Underwhelming Third Quarter Performance Berkshire Hathaway's recent third-quarter earnings report has raised eyebrows as the results fell short of analyst predictions. The earnings per share (EPS) came in at $4.68, whereas consensus estimates were looking for $4.89. Analysts have pointed to several factors influencing this underperformance. Insurance...

Continue Reading
Multitude SE Reports 34.5% EBIT Growth in 2024

Updated Category News Views 101

Multitude SE Reports Strong Growth in 2024 Key takeaways: The company continues to perform well, maintaining a robust cash position. Group revenue has risen by 17.0%, reaching EUR 128.8 million. All business units are reporting at least double-digit revenue growth. On track to meet EBIT guidance of EUR 67.5 million (+50%) for 2024. Multitude SE, a leading European FinTech...

Continue Reading
Discover How Cboe Global Markets Has Grown Over a Decade

Updated Category News Views 241

Understanding the Growth of Cboe Global Markets Cboe Global Markets has displayed remarkable performance in the stock market over the past decade. Specifically, the company has outperformed the market by an average of 2.96% annually, resulting in a substantial annual return of approximately 14.72%. Presently, its market capitalization stands at around $26.52 billion,...

Continue Reading